BUSINESSQUARTZ
Eli Lilly stock surged after its next-generation weight loss drug posted record results
Eli Lilly's stock surged following record results from its next-generation weight loss drug, retatrutide. Participants on the highest dose lost an average of 28.3% of their body weight over 80 weeks.
Related Signal
Adjacent reporting
- Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy
- New weight-loss shot appears to outperform other obesity drugs on market
- New obesity drug from Lilly delivers major weight loss
- Retatrutide results spark questions about how rapid weight loss affects the body
- New Weight Loss Drug Retatrutide Delivers Stunning Results
- STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug